Patents by Inventor Richard Yu-Cheng HUANG

Richard Yu-Cheng HUANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11919954
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: March 5, 2024
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Achal Pashine, Michael L. Gosselin, Aaron P. Yamniuk, Derek A. Holmes, Guodong Chen, Priyanka Apurva Madia, Richard Yu-Cheng Huang, Stephen Michael Carl
  • Patent number: 11919962
    Abstract: Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7R?). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: March 5, 2024
    Assignee: Bristol Myers-Squibb Company
    Inventors: Aaron Paul Yamniuk, Scott Ronald Brodeur, Ekaterina Deyanova, Richard Yu-Cheng Huang, Yun Wang, Alfred Robert Langish, Guodong Chen, Stephen Michael Carl, Hong Shen, Achal Mukundrao Pashine, Lin Hui Su
  • Publication number: 20220089720
    Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof.
    Type: Application
    Filed: January 11, 2019
    Publication date: March 24, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Xiao Min SCHEBYE, Mark J. SELBY, Michelle Minhua HAN, Christine BEE, Andy X. DENG, Anan CHUNTHARAPAI, Brigitte DEVAUX, Huiming LI, Paul O. SHEPPARD, Alan J. KORMAN, Daniel F. ARDOUREL, Ekaterina DEYANOVA, Richard Yu-Cheng HUANG, Guodong CHEN, Michelle KUHNE, Hong-An TRUONG
  • Publication number: 20220017627
    Abstract: Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7R?). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.
    Type: Application
    Filed: April 16, 2021
    Publication date: January 20, 2022
    Inventors: Aaron Paul Yamniuk, Scott Ronald Brodeur, Ekaterina Deyanova, Richard Yu-Cheng Huang, Yun Wang, Alfred Robert Langish, Guodong Chen, Stephen Michael Carl, Hong Shen, Achal Mukundrao Pashine, Lin Hui Su
  • Publication number: 20220002404
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TRENT-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
    Type: Application
    Filed: September 10, 2021
    Publication date: January 6, 2022
    Inventors: Achal PASHINE, Michael L. GOSSELIN, Aaron P. YAMNIUK, Derek A. HOLMES, Guodong CHEN, Priyanka Apurva MADIA, Richard Yu-Cheng HUANG, Stephen Michael CARL
  • Publication number: 20210403561
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TRENT-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
    Type: Application
    Filed: September 10, 2021
    Publication date: December 30, 2021
    Inventors: Achal PASHINE, Michael L. GOSSELIN, Aaron P. YAMNIUK, Derek A. HOLMES, Guodong CHEN, Priyanka Apurva MADIA, Richard Yu-Cheng HUANG, Stephen Michael CARL
  • Publication number: 20210363242
    Abstract: This disclosure provides a method for treating a subject afflicted with a tumor or a cancer, wherein the method comprises administering to the subject therapeutically effective amounts of an anti-TIM3 antibody, alone or in combination with an inhibitor of the PD-1 signaling pathway (e.g., anti-PD-1 antibody). In some embodiments, the antibody is administered as a flat dose or a weight-based dose.
    Type: Application
    Filed: January 15, 2019
    Publication date: November 25, 2021
    Applicant: Bristol-Myers Squibb Company
    Inventors: Xiao Min SCHEBYE, Mark J. SELBY, Michelle Minhua HAN, Christine BEE, Andy X. DENG, Anan CHUNTHARAPAI, Brigitte DEVAUX, Huiming LI, Paul O. SHEPPARD, Alan J. KORMAN, Daniel F. ARDOUREL, Ekaterina DEYANOVA, Richard Yu-Cheng HUANG, Guodong CHEN, Michelle Renne KUHNE, Hong-An TRUONG, Poliana PATAH, Jeffrey R. JACKSON, Ronald A. FLEMING
  • Patent number: 11155618
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: October 26, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Achal Pashine, Michael L. Gosselin, Aaron P. Yamniuk, Derek A. Holmes, Guodong Chen, Priyanka Apurva Madia, Richard Yu-Cheng Huang, Stephen Michael Carl
  • Patent number: 11008395
    Abstract: Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7R?). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: May 18, 2021
    Assignee: Bristol Myers-Squibb Company
    Inventors: Aaron Paul Yamniuk, Scott Ronald Brodeur, Ekaterina Deyanova, Richard Yu-Cheng Huang, Yun Wang, Alfred Robert Langish, Guodong Chen, Stephen Michael Carl, Hong Shen, Achal Mukundrao Pashine, Lin Hui Su
  • Publication number: 20200231687
    Abstract: Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7R?). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.
    Type: Application
    Filed: January 21, 2020
    Publication date: July 23, 2020
    Applicant: Bristol Myers-Squibb Company
    Inventors: Aaron Paul YAMNIUK, Scott Ronald BRODEUR, Ekaterina DEYANOVA, Richard Yu-Cheng HUANG, Yun WANG, Alfred Robert LANGISH, Guodong CHEN, Stephen Michael CARL, Hong SHEN, Achal Mukundrao PASHINE, Lin Hui SU